文献速递生殖医学

皮下与阴道黄体酮在人工周期冻融囊胚移植中的比较

Subcutaneous versus vaginal progesterone for vitrified-warmed blastocyst transfer in artificial cycles.
PubMed 文献 · Reprod Biomed Online · 2020-05-03

回顾性队列研究纳入214例人工周期冻融胚胎移植女性,其中107例接受皮下黄体酮,107例按年龄和治疗周期序次匹配接受阴道黄体酮。两组阳性妊娠试验率、活产或持续妊娠率及流产率均无显著差异。作者认为皮下黄体酮似乎是阴道黄体酮的有效替代方案,但需随机对照试验进一步明确其作用。

要点

  • 皮下黄体酮组与阴道黄体酮组的活产或持续妊娠率相似(39.3% vs 35.5%)。
  • 两组阳性妊娠试验率(64.5% vs 58.9%)和流产率(29% vs 25.5%)均无显著差异。
  • 作者认为皮下黄体酮似乎是冻融胚胎移植中阴道黄体酮的有效替代方案。

核心结论

  • 作者认为,在接受冻融胚胎移植的患者中,皮下黄体酮似乎是阴道黄体酮的有效替代方案。
  • 作者提出,需要开展随机对照试验比较皮下黄体酮与不同黄体酮制剂、给药途径和方案,以更好地明确其作用。

研究设计与样本

  • 回顾性队列研究,纳入214例女性,其中107例在人工周期冻融胚胎移植中接受皮下黄体酮,107例接受阴道黄体酮并按年龄和治疗周期序次匹配作为对照。
  • 所有胚胎均在人工周期中移植,从月经周期第2或第3天开始每日口服6 mg戊酸雌二醇。
  • 在 priming 第10天行经阴道超声,无论子宫内膜厚度如何,若呈三线征则开始皮下黄体酮50 mg/天或阴道黄体酮180 mg/天。
  • 在黄体酮给药第6天进行胚胎移植;雌二醇和黄体酮持续至移植后10天妊娠试验阴性或至妊娠第10周末。
  • 主要结局指标为活产或持续妊娠率。

主要发现

  • 两组基线特征相似。
  • 阳性妊娠试验率:皮下黄体酮组64.5% vs 阴道黄体酮组58.9%(P = 0.40;RR 1.1;95% CI 0.89至1.35)。
  • 活产或持续妊娠率:皮下黄体酮组39.3% vs 阴道黄体酮组35.5%(P = 0.57;RR 1.11;95% CI 0.78至1.56)。
  • 流产率:皮下黄体酮组29% vs 阴道黄体酮组25.5%(P = 0.68;RR 1.08;95% CI 0.76至1.55)。

临床怎么用

  • 作者认为皮下黄体酮似乎是冻融胚胎移植中阴道黄体酮的有效替代方案。
  • 作者提出需要随机对照试验比较皮下黄体酮与不同黄体酮制剂、给药途径和方案,以更好地明确其作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Does subcutaneous progesterone provide similar live birth or ongoing pregnancy rates as vaginal progesterone in frozen embryo transfer (FET) cycles? DESIGN: Retrospective cohort study (n = 214 women), consisting of 107 women who received subcutaneous progesterone for FET in artificial cycles and 107 women receiving vaginal progesterone who were matched for age and treatment cycle rank acted as controls. All embryos were transferred in an artificial cycle with 6 mg per day oral oestradiol valerate starting on the second or third day of the menstrual cycle. Patients underwent transvaginal ultrasound on the 10th day of priming, and subcutaneous progesterone (50 mg/day) or vaginal progesterone (180 mg/day) was started if the endometrium had a trilinear pattern regardless of its thickness. Embryo transfer was carried out on the sixth day of progesterone administration. Oestradiol and progesterone were continued until a negative pregnancy test, 10 days after the transfer, or until the completion of 10th gestational week. Main outcome measures were live birth or ongoing pregnancy rates. RESULTS: Baseline characteristics were similar between the groups. Positive pregnancy test rates (64.5% versus 58.9%; P = 0.40; RR 1.1; 95% CI 0.89 to 1.35), live birth or ongoing pregnancy rates (39.3% versus 35.5%; P = 0.57; RR 1.11; 95% CI 0.78 to 1.56) and miscarriage rates (29% versus 25.5%; P = 0.68; RR 1.08; 95% CI 0.76 to 1.55) were similar in the subcutaneous progesterone and vaginal progesterone groups, respectively. CONCLUSIONS: Subcutaneous progesterone seems to be an effective alternative to vaginal progesterone in patients undergoing FET. Randomized controlled trials comparing it with different progesterone preparations, routes and protocols are needed to better define its role.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Turkgeldi E, Hanege BY, Yildiz S, et al. Subcutaneous versus vaginal progesterone for vitrified-warmed blastocyst transfer in artificial cycles. Reprod Biomed Online. 2020. PMID: 32532668. doi:10.1016/j.rbmo.2020.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。